Hematopoietic stem cell transplantation for multiple myeloma beyond 2010

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Autologous stem cell transplantation (ASCT) is the standard frontline therapy for younger multiple myeloma patients, offering superior complete remission (CR) and event-free survival compared to chemotherapy.
• Achieving CR post-ASCT is crucial for patient benefit, with M-protein levels pre-transplant influencing CR likelihood.

Purpose of the Study:

• To evaluate the impact of novel agents on ASCT outcomes in multiple myeloma.
• To assess the role of optimized high-dose therapy in the era of novel agents.
• To review the advancements in allogeneic transplantation strategies for multiple myeloma.

Main Methods:

• Analysis of outcomes data for multiple myeloma patients undergoing ASCT with novel agent incorporation.
• Review of studies on reduced-intensity conditioning allogeneic transplantation.
• Evaluation of post-transplantation consolidation and maintenance strategies.

Main Results:

• Novel agents increase pre- and post-transplant CR rates, with bortezomib-containing regimens showing promise in poor-risk cytogenetics.
• Reduced-intensity conditioning allogeneic transplantation shows a progression-free survival plateau of 25-30% beyond 6 years.
• Post-transplant consolidation/maintenance with new drugs yields encouraging results.

Conclusions:

• High-dose therapy should be optimized, not replaced, in the era of novel agents for multiple myeloma.
• Reduced-intensity conditioning allogeneic transplantation is a viable option, with ongoing research focused on preparative regimens and GVHD/graft-versus-myeloma strategies.
• Further follow-up is needed to confirm the long-term survival impact of increased CR rates achieved with novel agents.